PROGRESSION-FREE SURVIVAL IS A ROBUST SURROGATE ENDPOINT OF OVERALL SURVIVAL IN IMMUNOTHERAPY TRIALS OF HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Cabibbo, Giuseppe [1 ]
Celsa, Ciro [2 ,3 ]
Enea, Marco [2 ]
Battaglia, Salvatore [2 ]
Rizzo, Giacomo [2 ]
Busacca, Anita [2 ]
Matranga, Domenica [2 ]
Attanasio, Massimo [2 ]
Reig, Maria [4 ]
Craxi, Antonio [5 ]
Camma, Calogero [3 ]
机构：
[1] Univ Palermo, Dipartimento Biomed Med & Interne Specialist Di B, Sez Gastroenterol & Epatol, Palermo, Italy
[2] Univ Palermo, Palermo, Italy
[3] Univ Palermo, Sect Gastroenterol & Hepatol, Dipartimento Promoz Salute Materno Infantile Med, Palermo, Italy
[4] Univ Barcelona, Hosp Clin, Barcelona Clin Liver Canc BCLC Grp, Liver Unit,Idibaps,Ciberehd, Barcelona, Spain
[5] Univ Palermo, Dibimis, Gastroenterolgy & Liver Unit, Palermo, Italy
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1068
引用
收藏
页码：649A / 649A
页数：1
相关论文
共 50 条
  • [31] Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
    Stefan Michiels
    Everardo D. Saad
    Marc Buyse
    Drugs, 2017, 77 : 713 - 719
  • [32] Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    CLINICAL CANCER RESEARCH, 2013, 19 (05) : 969 - 976
  • [33] Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
    Hirai, Takehiro
    Nemoto, Asuka
    Ito, Yoshinori
    Matsuura, Masaaki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 189 - 198
  • [34] Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Friedlander, Michael
    Marschner, Ian
    Simes, John
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] EVALUATION OF PROGNOSTIC FACTORS OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
    Bramuzzo, I.
    Gerussi, A.
    Maier, S.
    Bianco, C.
    Romanin, A.
    Pasini, C. Laghi
    Barghini, V.
    Scata, L.
    Donnini, D.
    Uzzau, A.
    Vit, A.
    Sechi, L. A.
    Soardo, G.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E217 - E217
  • [36] Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
    Takehiro Hirai
    Asuka Nemoto
    Yoshinori Ito
    Masaaki Matsuura
    Breast Cancer Research and Treatment, 2020, 181 : 189 - 198
  • [37] OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL IN ONCOLOGY CLINICAL TRIALS
    Aissaoui, A.
    Bin Sawad, A.
    Turkistani, F.
    Aissaoui, N.
    VALUE IN HEALTH, 2016, 19 (07) : A717 - A717
  • [38] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
  • [39] A trial-level correlation analysis of progression-free survival as a surrogate for overall survival in the immunotherapy era.
    Yekeduz, Emre
    Koksoy, Elif Berna
    Akbulut, Hakan
    Utkan, Gungor
    Urun, Yuksel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Progression-Free Survival Remains Debatable Endpoint in Cancer Trials
    Tuma, Rabiya
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (21) : 1439 - 1441
12345